美国制药业向医生支付的款项与PARP抑制剂处方之间的关联
该研究利用2017至2021年美国Open Payments数据库和Medicare Part D数据库的面板数据,纳入1686名开具奥拉帕利、芦卡帕利或尼拉帕利超过10次索赔的医生。结果显示,68.7%的医生收到过PARP抑制剂制造商提供的非研究性付款,且收到付款与开具奥拉帕利(OR 1.30)、芦卡帕利(OR 2.07)和尼拉帕利(OR 1.49)的 odds 升高相关。
要点
- 68.7%的合格处方医生在2017至2021年间收到过PARP抑制剂制造商的非研究性付款。
- 收到付款与开具奥拉帕利(OR 1.30)、芦卡帕利(OR 2.07)和尼拉帕利(OR 1.49)的 odds 升高显著相关。
- 奥拉帕利和芦卡帕利的年度付款次数与处方量及Medicare支出之间存在剂量-反应关系。
核心结论
- 在美国,PARP抑制剂制造商向处方医生提供的非研究性付款与奥拉帕利和芦卡帕利的处方量及Medicare支出增加显著相关。
研究设计与样本
- 面板数据分析,使用2017至2021年公开的Open Payments数据库和Medicare Part D数据库。
- 纳入所有对奥拉帕利、芦卡帕利或尼拉帕利报告超过10次索赔的医生,共1686名合格处方医生。
主要发现
- 1686名合格处方医生中,68.7%在2017至2021年间收到过至少一次与三种PARP抑制剂中任一种相关的制造商非研究性付款。
- 每位医生每年收到的付款中位数:奥拉帕利57美元,芦卡帕利39美元,尼拉帕利62美元。
- 收到付款与开具奥拉帕利的 odds 升高相关(OR 1.30,95% CI 1.14-1.48,p<0.001)。
- 收到付款与开具芦卡帕利的 odds 升高相关(OR 2.07,95% CI 1.58-2.72,p<0.001)。
- 收到付款与开具尼拉帕利的 odds 升高相关(OR 1.49,95% CI 1.22-1.81,p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the association between industry payments to physicians related to poly (ADP-ribose) polymerase inhibitors (PARPis) and physicians' prescribing behaviors for PARPis. METHODS: This panel-data analysis used the publicly accessible Open Payments Database and Medicare Part D database between 2017 and 2021. All physicians who reported >10 claims for either olaparib, rucaparib, or niraparib were included in this study. Non-research payments for the PARPis to the physicians from the PARPi manufacturers were extracted from the Open Payments Database. Associations between the physicians' receipt of payments and likelihood of prescribing PARPis were assessed with logistic generalized estimating equations (GEEs). Dose-response associations between the number of payments and prescription volumes and Medicare expenditures were evaluated with linear GEEs. RESULTS: Of the 1686 eligible physician prescribers, 68.7% received one or more non-research payments related to any of the three PARPis from the manufacturers between 2017 and 2021. Median annual payments per physician were $57 for olaparib, $39 for rucaparib, and $62 for niraparib. Receipt of payments for each PARPi was associated with higher odds of prescribing olaparib (odds ratio [OR]: 1.30 [95% CI: 1.14-1.48], p < 0.001), rucaparib (OR: 2.07 [95% CI: 1.58-2.72], p < 0.001), and niraparib (OR: 1.49 [95% CI: 1.22-1.81], p < 0.001). Dose-response effects were observed between the number of annual payments and the number of prescriptions and/or Medicare expenditures for olaparib and rucaparib. CONCLUSION: Non-research payments to physician prescribers of PARP inhibitors from the manufacturers were significantly associated with increased prescriptions and Medicare expenditures for olaparib and rucaparib in the United States.
引用
- Murayama A, Marshall DC. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States. Gynecol Oncol. 2023. PMID: 38147713. doi:10.1016/j.ygyno.2023.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。